Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents

Blood

Volumn 129, Issue 13, 2017, Pages 1823-1830

  Asshoff, Malte ^a   Petzer, Verena ^a   Warr, Matthew R ^b   Haschka, David ^a   Tymoszuk, Piotr ^a   Demetz, Egon ^a   Seifert, Markus ^a   Posch, Wilfried ^a   Nairz, Manfred ^a   Maciejewski, Pat ^b   Fowles, Peter ^b   Burns, Christopher J ^b,c   Smith, Gregg ^b   Wagner, Kay Uwe ^d   Weiss, Guenter ^a   Whitney, J Andrew ^b   Theurl, Igor ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b GILEAD SCIENCES   (United States)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; FERROPORTIN 1; HEPCIDIN; INTERLEUKIN 6; IRON; JANUS KINASE 2; MOMELOTINIB; RUXOLITINIB; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; ACTIVIN RECEPTOR 1; ALK2 PROTEIN, RAT; BENZAMIDE DERIVATIVE; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PYRIMIDINE DERIVATIVE;

ANEMIA; ANEMIA OF CHRONIC DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; IRON BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHRONIC DISEASE; COMPLICATION; LIVER CELL; METABOLISM; MYELOID METAPLASIA;

ACTIVIN RECEPTORS, TYPE I; ANEMIA; ANIMALS; BENZAMIDES; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; CHRONIC DISEASE; HEPATOCYTES; HEPCIDINS; IRON; PRIMARY MYELOFIBROSIS; PYRIMIDINES; RATS;

EID: 85019896728     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-09-740092     Document Type: Article

References (32)

1. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93(4):1721-1741.
2. Krause A, Neitz S, Mägert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000; 480(2-3):147-150.
3. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811-7819.
4. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001; 276(11):7806-7810.
5. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142(1): 24-38.
6. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093.
7. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009;113(21): 5277-5286.
8. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023.
9. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2005;2(6): 399-409.
10. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41(4):482-487.
11. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41(4):478-481.
12. Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest. 2013;123(6):2337-2343.
13. Steinbicker AU, Bartnikas TB, Lohmeyer LK, et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood. 2011;118(15):4224-4230.
14. Steinbicker AU, Sachidanandan C, Vonner AJ, et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011;117(18):4915-4923.
15. Theurl I, Schroll A, Nairz M, et al. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica. 2011;96(12):1761-1769.
16. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87(1): 25-33.
17. Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013;88(4): 312-316.
18. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6): 1322-1327.
19. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
20. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9): 799-807.
21. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385-395.
22. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93(3):397-409.
23. De Domenico I, Lo E, Ward DM, Kaplan J. Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2 [published correction appears in Proc Natl Acad Sci USA. 2012;109(19):7583-7586]. Proc Natl Acad Sci USA. 2009;106(10):3800-3805.
24. Ross SL, Tran L, Winters A, et al. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab. 2012;15(6): 905-917.
25. Theurl I, Schroll A, Sonnweber T, et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood. 2011;118(18):4977-4984.
26. Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, Wagner KU. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis. 2004;40(1):52-57.
27. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA. 2005;102(6):1906-1910.
28. Wrana JL. Signaling by the TGFb superfamily. Cold Spring Harb Perspect Biol. 2013;5(10): a011197.
29. Canali S, Core AB, Zumbrennen-Bullough KB, et al. Activin B induces noncanonical SMAD1/5/8 signaling via BMP type I receptors in hepatocytes: evidence for a role in hepcidin induction by inflammation in male mice. Endocrinology. 2016; 157(3):1146-1162.
30. Besson-Fournier C, Gineste A, Latour C, et al. Hepcidin upregulation by inflammation is independent of Smad1/5/8 signaling by activin B. Blood. 2017;129(4):533-536.
31. Strati P, Pemmaraju N, Estrov Z, et al. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res. 2014;38(10): 1212-1216.
32. Vainchenker W, Favale F. Myelofibrosis, JAK2 inhibitors and erythropoiesis. Leukemia. 2013; 27(6):1219-1223.